PEAR.Q Stock Overview
A commercial-stage healthcare company, develops and sells software-based medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Pear Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.000001 |
| Beta | 8.21 |
| 11 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.97% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17
Recent updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Aug 18Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic
Aug 03Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
May 21Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Apr 04Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Jan 10Shareholder Returns
| PEAR.Q | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -8.8% | -2.1% |
| 1Y | -100.0% | 6.6% | 29.6% |
Return vs Industry: PEAR.Q underperformed the US Healthcare Services industry which returned -3.2% over the past year.
Return vs Market: PEAR.Q underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| PEAR.Q volatility | |
|---|---|
| PEAR.Q Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PEAR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PEAR.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 200 | n/a | peartherapeutics.com |
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology.
Pear Therapeutics, Inc. Fundamentals Summary
| PEAR.Q fundamental statistics | |
|---|---|
| Market cap | US$142.00 |
| Earnings (TTM) | -US$75.49m |
| Revenue (TTM) | US$12.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs PEAR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEAR.Q income statement (TTM) | |
|---|---|
| Revenue | US$12.69m |
| Cost of Revenue | US$7.39m |
| Gross Profit | US$5.30m |
| Other Expenses | US$80.79m |
| Earnings | -US$75.49m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 41.75% |
| Net Profit Margin | -594.70% |
| Debt/Equity Ratio | 89.7% |
How did PEAR.Q perform over the long term?
See historical performance and comparison